Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and behavioral causes of obesity, has been co-developed with [...] (OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration